These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38753983)

  • 1. Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of
    Rueedi G; Panchaud P; Friedli A; Specklin JL; Hubschwerlen C; Blumstein AC; Caspers P; Enderlin-Paput M; Jacob L; Kohl C; Locher HH; Pfaff P; Schmitt C; Seiler P; Ritz D
    J Med Chem; 2024 Jun; 67(11):9465-9484. PubMed ID: 38753983
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring novel microbial metabolites and drugs for inhibiting
    Abouelkhair AA; Seleem MN
    mSphere; 2024 Jul; 9(7):e0027324. PubMed ID: 38940508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
    Skinner K; Birchall S; Corbett D; Thommes P; Locher HH
    J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrapotent Inhibitor of
    Naclerio GA; Abutaleb NS; Li D; Seleem MN; Sintim HO
    J Med Chem; 2020 Oct; 63(20):11934-11944. PubMed ID: 32960605
    [No Abstract]   [Full Text] [Related]  

  • 8. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Caspers P; Bruyère T; Schroeder S; Pfaff P; Knezevic A; Keck W; Ritz D
    Antimicrob Agents Chemother; 2014; 58(2):901-8. PubMed ID: 24277035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
    Lesniak NA; Schubert AM; Sinani H; Schloss PD
    mSphere; 2021 May; 6(3):. PubMed ID: 33952668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of live biotherapeutics against
    Zhang Y; Saint Fleur A; Feng H
    Gut Microbes; 2022; 14(1):2052698. PubMed ID: 35319337
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic.
    Scaiola A; Leibundgut M; Boehringer D; Caspers P; Bur D; Locher HH; Rueedi G; Ritz D
    Sci Rep; 2019 Apr; 9(1):5634. PubMed ID: 30948752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection.
    Cho Y; Park K; Park J; An J; Myung H; Yoon H
    Int J Antimicrob Agents; 2024 Aug; 64(2):107222. PubMed ID: 38810936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Colonization Resistance Against Clostridioides difficile.
    Pike CM; Theriot CM
    J Infect Dis; 2021 Jun; 223(12 Suppl 2):S194-S200. PubMed ID: 33326565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of a 1,2,4-Oxadiazole with Potent and Specific Activity against
    Barbachyn MR
    J Med Chem; 2023 Oct; 66(20):13888-13890. PubMed ID: 37823241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection model.
    Tague AJ; Putsathit P; Hutton ML; Hammer KA; Wales SM; Knight DR; Riley TV; Lyras D; Keller PA; Pyne SG
    Eur J Med Chem; 2019 May; 170():203-224. PubMed ID: 30901686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadazolid for the treatment of Clostridium difficile.
    Endres BT; Bassères E; Alam MJ; Garey KW
    Expert Opin Investig Drugs; 2017 Apr; 26(4):509-514. PubMed ID: 28286992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.